| 李海燕,李玉娟,曹淑琴,杨 媛,郝光军.培美曲塞联合顺铂对老年Ⅲ~Ⅳ期非小细胞肺癌患者血清CEA，CYFRA21-1，p-ERK，VEGF 及AnnexinⅡ水平的影响[J].,2017,17(19):3758-3761 |
| 培美曲塞联合顺铂对老年Ⅲ~Ⅳ期非小细胞肺癌患者血清CEA，CYFRA21-1，p-ERK，VEGF 及AnnexinⅡ水平的影响 |
| Influence of Pemetrexed Combined Cisplatin on Serum Levels of CEA, CYFRA21-1, p-ERK, VEGF and Annexin Ⅱ in Elderly Patients with Ⅲ~Ⅳ Stage Non-small Cell Lung Cancer |
| 投稿时间：2016-12-28 修订日期：2017-01-21 |
| DOI：10.13241/j.cnki.pmb.2017.19.040 |
| 中文关键词: Ⅲ~Ⅳ期非小细胞肺癌 培美曲塞 顺铂 |
| 英文关键词: Ⅲ ~ Ⅳ non-small cell lung cancer Pemetrexed Cisplatin |
| 基金项目:青海省自然科学基金项目（BK20091124） |
|
| 摘要点击次数: 332 |
| 全文下载次数: 180 |
| 中文摘要: |
| 摘要 目的：探讨培美曲塞联合顺铂对老年Ⅲ~Ⅳ期非小细胞肺癌患者血清癌胚抗原（CEA），细胞角质素片段抗原21-1(CYFRA21-1)，磷酸化细胞外信号调节激酶（p-ERK），血管内皮生长因子（VEGF）及膜联蛋白Ⅱ（AnnexinⅡ）水平的影响。方法：120例老年Ⅲ~Ⅳ期非小细胞肺癌患者按抽签法分为对照组（n=60）与观察组（n=60），对照组予以多西紫衫醇联合顺铂治疗，观察组予以培美曲塞联合顺铂治疗，比较两组CEA，CYFRA21- 1，p-ERK，VEGF，AnnexinⅡ，基质金属蛋白酶-2（MMP-2）及转化生长因子β1（TGF-β1），NK细胞，CD3+，CD4+，临床疗效和不良反应。结果：治疗后，观察组CEA，CYFRA21- 1，p-ERK，VEGF，An- nexinⅡ，MMP-2及TGF-β1低于对照组，差异有统计学意义（P<0.05）。观察组NK细胞，CD3+及CD4+高于对照组（P<0.05）。观察组临床疗效、不良反应均优于对照组（P<0.05）。结论：培美曲塞联合顺铂化疗可降低老年Ⅲ~Ⅳ期非小细胞肺癌患者血清CEA，CYFRA21- 1，p-ERK，VEGF及AnnexinⅡ水平，控制肿瘤进展，值得推广。 |
| 英文摘要: |
| ABSTRACT Objective: To research the influence of pemetrexed combined cisplatin on the serum levels of carcinoembryonic anti- gen (CEA), cell keratin fragments antigen 21-1 (CYFRA21-1), phosphorylated extracellular signal regulating kinase (p-ERK), vascular endothelial growth factor (VEGF) and annexin Ⅱ in elderly patients with Ⅲ-Ⅳ stage non-small cell lung cancer. Methods: 120 cases with Ⅲ-Ⅳ stage non-small cell lung cancer were divided into control group (n=60) and observation group (n=60). The patients in the control group were treated with docetaxel combined cisplatin, while the patients in the observation group were treated with pemetrexed and cisplatin. Then the serum levels of CEA, CYFRA21-1, p-ERK, VEGF, annexin Ⅱ, matrix metalloproteinase-2 (MMP-2), transform- ing growth factor-β1 (TGF-β1), NK cells, CD3+ and CD4+, the clinical efficacy and adverse reactions between the two groups were ob- served and compared. Results: After treatment, the serum levels of CEA, CYFRA21-1, p-ERK, VEGF, annexin Ⅱ, MMP-2 and TGF-β1 in the observation group were lower than those of the control group, and the differences were statistically significant (P<0.05). The NK cells, CD3+ and CD4+ in the observation group were higher than those of the control group (P<0.05). The clinical efficacy and adverse re- actions in the observation group were better than those of the control group (P<0.05). Conclusion: Pemcitabine combined cisplatin in treatment patients with stage Ⅲ~Ⅳ non-small cell lung cancer, which can reduce the serum levels of CEA, CYFRA21-1, p-ERK, VEGF and annexin Ⅱ, and control the tumor progression. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
